EC Approves SYMKEVI and KALYDECO for Cystic Fibrosis

 

On November 27, biotechnology company Vertex Pharmaceuticals Inc. (“Vertex”) announced the approval of SYMKEVI with KALYDECO for the treatment of pediatric patients with cystic fibrosis (CF), says GuruFocus. The European Commission (EC) approved the use of this therapeutic combination for patients ages 6 and up. Specifically, SYMKEVI and KALYDECO are designed for patients with at least one F508del gene mutation. Overall, this is one of the more common genetic mutations associated with CF.

SYMKEVI and KALYDECO

Together, SYMKEVI and KALYDECO represent one of the first therapeutic options for CF that addresses this specific genetic component. Although it is already approved for patients over the age of 12, this approval marks a new available treatment for younger patients. The combination will first be available to patients in Germany. However, it will later be available in Denmark, Ireland, and the United Kingdom. Outside of these countries, Vertex is working to bring SYMKEVI and KALYDECO to patients in need.

The drugs work by normalizing defective CFTR protein, enabling it to reach cells, and prompting it to function correctly.

Cystic Fibrosis (CF)

As a recessive genetic disorder, cystic fibrosis is caused when someone inherits two defective or mutated CFTR genes, one from each parent. There are a multitude of gene mutations that can impact salt regulation, leading to cystic fibrosis. Normally, our systems have “healthy” mucus, which is slippery. But people with cystic fibrosis have thick, sticky mucus that accumulates in the system. As this mucus accumulates, it clogs airways, traps bacteria, and causing a multitude of respiratory issues. Additionally, it stops digestive enzymes from being released, causing poor nutrient absorption. Cystic fibrosis affects Caucasians at a higher rate than other ethnicities. Symptoms include:

  • Male infertility
  • Frequent lung infections
  • Chronic coughing or wheezing
  • Shortness of breath / difficulty breathing
  • Poor growth
  • Abdominal pain
  • Difficulty gaining weight
  • Exercise intolerance
  • Stuffy nose
  • Salty skin
  • Constipation or greasy-looking bowel movements
Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email